Efforts to vaccinate vulnerable populations against respiratory syncytial virus (RSV) faced an uphill battle this season. However, now a new study by researchers at New York Institute of Technology College of Osteopathic Medicine (NYITCOM) could help to combat RSV vaccine misinformation and quell vaccine…
Tag: Food and Drug Administration approval
Annual Medicare spending could increase by $2 to $5 billion if Medicare expands coverage for dementia drug lecanemab
The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.